Optic Nerve Disorders Treatment Market to Witness Robust Growth Due To Increasing Prevalence of Eye Disorders
Optic nerve disorder is a rare autoimmune disease that indicates degeneration of the optic nerve. There are many types of optic nerve disorders, such as optic nerve atrophy, optic neuritis, and glaucoma. An individual with glaucoma can use eye drops, take oral medications, or undergo eye surgery such as laser therapy. Antibiotics such as tetracycline, isoniazid, and ethambutol cause optic neuritis. In some cases, steroid-based medications are used to reduce inflammation in the optic nerve. However, once damaged, the optic nerve cannot be repaired since the damage is irreversible. The optic nerve disorders treatment market is expected to witness robust growth due to increasing prevalence of the disease.
Glaucoma is the second most common cause of blindness
globally. According to the Glaucoma Research Foundation (GRF), a national
non-profit organization, by 2040, around 1,118 million people worldwide will
have glaucoma. According to the World Health Organization (WHO), there are
several types of glaucoma, however, the two most common are, primary open angle
glaucoma (POAG) and angle closure glaucoma (ACG). More than 90% of cases of
glaucoma remain undiagnosed in the community. Thus, with the increasing
prevalence, the demand for optic nerve disorders treatment is also increasing.
For instance, in August 2020, The U.S. Food and Drug
Administration (USFDA) approved Enspryng (satralizumab-mwge) for the treatment
of neuromyelitis optic spectrum disorder in adults with a particular antibody. Enspryng
is the third approved treatment for the disorder. Moreover, in June 2020, FDA
approved Uplizna (inebilizumab-cdon) injection for intravenous use for the
treatment of neuromyelitis optic spectrum disorder in adult patients with a
particular antibody. Uplizna is the second approved treatment for the disorder.
Therefore, increasing drug approvals by USFDA for treatment of optic nerve
disorders are expected to drive growth of the optic nerve disorders treatment
market.
Moreover, growth of the optic nerve disorders treatment market
is driven by the increasing prevalence of eye disorders worldwide, especially
in North America. According to the Centers for Disease Control and Prevention
(CDC), around 12 million Americans, aged 40 years and over, have vision
impairment. Thus, demand for optic nerve disorders treatment is increasing with
the increasing prevalence of eye disorders. For instance, in February 2021, Viela
Bio reported updated safety, efficacy, and long-term use results of UPLIZNA
(inebilizumab-cdon), including interim data from the open-label extension
period of the pivotal N-MOmentum trial in patients with neuromyelitis optic
spectrum disorder.
However, side effects associated with steroid drugs and optic
nerve disorder drugs are expected to restrain the optic nerve disorders
treatment market growth.
Comments
Post a Comment